The Non-Sterile Outsourcing Market: Growth, Trends, and Forecast for 2023–2033
The Non-Sterile Outsourcing Market Size is Anticipated to Exceed USD 11.78 Billion by 2033, Growing at a CAGR of 4.72% from 2023 to 2033. A compounded pharmaceutical product that contains one or more active components can be either sterile or non-sterile. Expanding drug development costs, decreasing internal capabilities, stricter governmental regulations, and low-cost service delivery to contract research organizations (CROs) and contract manufacturing organizations (CMOs) are among the key reasons driving market expansion.